Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 09, 2024 10:27am

109 Views

Post# 36214652

RE:RE:RE:“Second mouse gets the cheese “

Sept. 9, 2024 /PRNewswire/ -- Roche announced today the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators, ultimately to provide the diagnostic tools to help clinicians improve the lives of patients worldwide.

ONCY has been contributing to the development of biomarkers to address the cancers that Roche is interested in pursing.

The collaborators are:

Deep Bio: Algorithm for prostate cancer detection, grading, and tumour quantification
DiaDeep: Algorithms for breast cancer biomarker quantification
Lunit: Tumour proportion score (TPS) analysis for non-small cell lung cancer
Mindpeak: Algorithms for breast biomarkers and pan tumour PD-L1 for lung, gastric, esophageal, bladder and breast cancers
Owkin: Algorithm for the screening of microsatellite stability in colorectal cancer
Qritive: Algorithms for screening and grading of prostate cancer, analysing lymph nodes for metastasis, and screening for colon cancer
Sonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancer
Stratipath: Algorithm for risk profiling of invasive breast cancer